Barbara L Smith Selected Research

Barbara L Smith Research Topics

Disease

73	Breast Neoplasms (Breast Cancer) 05/2024 - 01/2003
47	Neoplasms (Cancer) 05/2024 - 01/2003
17	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2022 - 01/2008
6	Residual Neoplasm 05/2021 - 03/2016
5	Neoplasm Metastasis (Metastasis) 07/2013 - 09/2004
4	Carcinoma (Carcinomatosis) 01/2022 - 10/2009
4	Margins of Excision 06/2020 - 07/2003
4	Lymphedema (Milroy Disease) 02/2016 - 10/2012
3	Pathologic Complete Response 01/2020 - 10/2017
3	Hyperplasia 09/2017 - 12/2012
2	COVID-19 03/2022 - 10/2020
2	Cicatrix (Scar) 01/2019 - 08/2010
2	Breast Carcinoma In Situ 12/2012 - 10/2009
2	Leukemia 10/2012 - 04/2003
1	Infections 05/2023
1	Necrosis 05/2023
1	Hypersensitivity (Allergy) 01/2022
1	Anaphylaxis (Anaphylactic Shock) 01/2022
1	Contracture 01/2022
1	Radiation Pneumonitis 07/2013
1	Fatigue 07/2013
1	Postoperative Nausea and Vomiting (PONV) 04/2013
1	Pain (Aches) 04/2013
1	Hypoxia (Hypoxemia) 09/2012
1	Inflammation (Inflammations) 09/2012
1	Gynecomastia 11/2008
1	Neoplasm Micrometastasis 01/2008
1	Male Breast Neoplasms (Male Breast Cancer) 12/2007
1	Telangiectasis (Telangiectasia) 11/2006
1	Joint Diseases (Joint Disease) 01/2004
1	Hemorrhage 07/2003
1	Hematoma 07/2003
1	Abscess 07/2003

Drug/Important Bio-Agent (IBA)

8	Estrogen ReceptorsIBA 10/2020 - 09/2004
5	Tamoxifen FDA LinkGeneric 11/2021 - 09/2004
4	Protons (Proton)IBA 01/2022 - 11/2006
3	Peptide Hydrolases (Proteases)FDA Link 05/2021 - 06/2020
3	Progesterone Receptors (Progesterone Receptor)IBA 03/2012 - 05/2008
3	Phenobarbital (Luminal)FDA Link 03/2012 - 05/2008
2	N-acetyltalosaminuronic acid (NAT)IBA 11/2020 - 01/2020
2	human ERBB2 proteinIBA 10/2009 - 01/2003
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2003 - 01/2003
2	Doxorubicin (Adriamycin)FDA LinkGeneric 04/2003 - 01/2003
2	Paclitaxel (Taxol)FDA LinkGeneric 04/2003 - 01/2003
1	PlasticsIBA 03/2022
1	Contrast MediaIBA 01/2022
1	Coloring Agents (Dyes)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 10/2021
1	larotrectinibIBA 10/2021
1	TropomyosinIBA 10/2021
1	entrectinibIBA 10/2021
1	N,N- dimethyl- N- hexadecyl- 1- octadecylammonium (DDAC)IBA 12/2018
1	pertuzumabIBA 12/2018
1	CathepsinsIBA 09/2018
1	Biomarkers (Surrogate Marker)IBA 10/2017
1	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 01/2016
1	Narcotics (Narcotic Analgesics)IBA 04/2013
1	Hyaluronic Acid (Hyaluronan)IBA 09/2012
1	CollagenIBA 09/2012
1	Epidermal Growth Factor (EGF)IBA 03/2012
1	A-factor (Streptomyces)IBA 11/2009
1	Hormones (Hormone)IBA 11/2008
1	Adenosine Triphosphate (ATP)IBA 11/2004
1	bromopyruvateIBA 11/2004
1	Alkylating AgentsIBA 11/2004
1	Pyruvic Acid (Pyruvate)IBA 11/2004
1	Lactic Acid (Lactate)FDA LinkGeneric 11/2004
1	Glucose (Dextrose)FDA LinkGeneric 11/2004
1	Diclofenac (SR 38)FDA LinkGeneric 01/2004
1	Trastuzumab (Herceptin)FDA Link 01/2003
1	AnthracyclinesIBA 01/2003

Therapy/Procedure

36	Segmental Mastectomy (Lumpectomy) 07/2023 - 09/2004
32	Mastectomy (Mammectomy) 05/2024 - 09/2004
18	Therapeutics 10/2020 - 01/2003
17	Radiotherapy 05/2023 - 07/2003
8	Mammaplasty (Breast Reconstruction) 03/2022 - 08/2014
7	Neoadjuvant Therapy 11/2020 - 10/2005
6	Lymph Node Excision (Lymph Node Dissection) 02/2016 - 10/2005
5	Prophylactic Mastectomy 01/2020 - 08/2008
5	Drug Therapy (Chemotherapy) 09/2013 - 01/2003
3	Proton Therapy 10/2019 - 07/2013
3	Chemoprevention 09/2017 - 12/2012
2	Adjuvant Chemotherapy 01/2020 - 04/2003
2	Brachytherapy 07/2012 - 07/2003
1	Tissue Expansion Devices (Tissue Expander) 05/2023
1	Radio Frequency Identification Device 11/2020
1	Operative Surgical Procedures 10/2020
1	Immunotherapy 09/2012
1	Modified Radical Mastectomy (Mastectomy, Modified) 12/2007
1	Catheters 07/2003
1	Combination Drug Therapy (Combination Chemotherapy) 04/2003